Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer’s disease: preclinical proof of concept
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Microglia significantly contribute to the pathophysiology of Alzheimer's disease but an effective microglia-targeted therapeutic approach is not yet available clinically. The potassium channels Kv1.3 and Kir2.1 play important roles in regulating immune cell functions and have been implicated by in vitro studies in the 'M1-like pro-inflammatory' or 'M2-like anti-inflammatory' state of microglia, respectively. We here found that amyloid-β oligomer-induced expression of Kv1.3 and Kir2.1 in cultured primary microglia. Likewise, ex vivo microglia acutely isolated from the Alzheimer's model 5xFAD mice co-expressed Kv1.3 and Kir2.1 as well as markers traditionally associated with M1 and M2 activation suggesting that amyloid-β oligomer induces a microglial activation state that is more complex than previously thought. Using the orally available, brain penetrant small molecule Kv1.3 blocker PAP-1 as a tool, we showed that pro-inflammatory and neurotoxic microglial responses induced by amyloid-β oligomer required Kv1.3 activity in vitro and in hippocampal slices. Since we further observed that Kv1.3 was highly expressed in microglia of transgenic Alzheimer's mouse models and human Alzheimer's disease brains, we hypothesized that pharmacological Kv1.3 inhibition could mitigate the pathology induced by amyloid-β aggregates. Indeed, treating APP/PS1 transgenic mice with a 5-month oral regimen of PAP-1, starting at 9 months of age, when the animals already manifest cognitive deficits and amyloid pathology, reduced neuroinflammation, decreased cerebral amyloid load, enhanced hippocampal neuronal plasticity, and improved behavioural deficits. The observed decrease in cerebral amyloid deposition was consistent with the in vitro finding that PAP-1 enhanced amyloid-β uptake by microglia. Collectively, these results provide proof-of-concept data to advance Kv1.3 blockers to Alzheimer's disease clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
In the citing paper
“Kv1.3 channel blockade by the small molecule Pap1 was also found to mitigate Aβ deposition and improve neurobehavioral measures in AD mouse models [49].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337 · cited 2×
“immune system, which acquire stable phenotypes after subtype differentiation or class-switching, cells of the innate immune system such as microglia are highly plastic and typically do not acquire a stable phenotype that can be readily categorized by specific markers or signature genes (Murray et al., 2014; Bohlen et…”
BackgroundNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“A gen- erally accepted hypothesis states that activated microglia re- lease cytotoxic substances and pro-inflammatory cytokines that cause neuronal damage and aggravate Alzheimer’s dis- ease pathology (Heneka et al., 2015).”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“Several key conclusions can be drawn from our study: (i) soluble AbO, the highly toxic amyloid-b species implicated as one of the principal initiators of Alzheimer’s disease phenotypes (Selkoe and Hardy, 2016), enhances microglial Kv1.”
BackgroundStructural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 2×
“1, another K + channel often expressed in myeloid cells and involved in regulating their function (Kettenmann et al., 2011; Feske et al., 2015), was highly upregulated (Nguyen et al.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“Alzheimer’s mouse model 5xFAD (Oakley et al., 2006), in which AbO is the major toxic amyloid-b species able to”
BackgroundMethodDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Production and administration of amyloid-b oligomer Amyloid-b oligomer (AbO) was prepared following a standard procedure (Lambert et al., 1998) except that the amyloid-b1-42 peptide (Bachem) was diluted with Opti-MEM culture medium instead of the F12 medium originally described, before incubation…”
MethodNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 3×
“…form part of the age-related changes in microglial function, documented by several lines of investigation, such as altered responses to amyloid-b aggregates or downregulation of ‘sensome’ genes (Hickman et al., 2008, 2013; Cameron et al., 2012; Heneka et al., 2013; Johansson et al., 2015).”
BackgroundIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“A network-based analysis of whole-genome gene-expression profiling and genotypic data obtained from 1647 Alzheimer’s disease and non-demented brain samples highlighted the immune/ microglia module as the molecular system most strongly associated with the pathophysiology of Alzheimer’s disease (Zhang et al., 2013).”
BackgroundMethodJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“Similar results were obtained using the other Alzheimer’s transgenic model called APP/PS1 (Jankowsky et al., 2004) (Supplementary Fig.”
Result
Cited by
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
“3 is highly expressed in transgenic AD mouse models and AD patients’ brains (Maezawa et al., 2018).”
BackgroundRangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
“shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
BackgroundSelf-citationRen, C., Li, D., Zhou, Q., & Hu, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119752 · Cited by 225
Cui, W., Sun, C., Ma, Y., Wang, S., Wang, X., & Zhang, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00444 · Cited by 220
NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology
He, X., Yang, W., Zeng, Z., Wei, Y., Gao, J., Zhang, B., Li, L., Liu, L., Wan, Y., Zeng, Q., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0260-y · Cited by 150
Metadata
- Authors
- Maezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., & Jin, L.-W.
- Affiliations
- University of California Davis Medical Center (US)
- University of California, Davis (US)
- Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, 2805 50th Street, Sacramento, CA 95817, USA
- Emory University (US)
- Corresponding author
- Maezawa, Izumi
- Wulff, Heike
- Jin, Lee-Way
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-18
- Volume
- 141
- Issue
- 2
- Pages
- 596-612
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5837198
- OpenAlex
- W2780797805
- Cited by
- 125
- References
- 78
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 15 · 2023: 15 · 2022: 17 · 2021: 24 · 2020: 14 · 2019: 7 · 2018: 9
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Kv1.3 potassium channel, Kir2.1, microglia, Alzheimer's disease, amyloid-beta oligomers, PAP1, microglial activation, macrophage polarization, neuroinflammation, cerebral amyloid deposition, APP/PS1 mice, hippocampal plasticity, microglia-targeted therapy
- MeSH terms
- Alzheimer Disease, Animals, Animals, Newborn, Avoidance Learning, Cells, Cultured, Disease Models, Animal, Exploratory Behavior, Ficusin, Gene Expression Regulation, Membrane Potentials, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Potassium Channel Blockers, Mice, Kv1.3 Potassium Channel, Shab Potassium Channels, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.